Scholarlink

Background and purpose <p>Non-functioning pituitary adenomas (NFPAs) have an unpredictable clinical course, with recurrence and progression posing significant challenges. This study aims to evaluate progression-free survival (PFS) and identify predictors and patterns of tumor progression.</p> Methods <p>We conducted a retrospective multicenter study including 472 patients with NFPAs &gt; 1&#xa0;cm from 17 Spanish hospitals (416 surgical, 56 conservative management). Tumor progression was defined as &gt; 20% increase in size, &gt;2&#xa0;mm growth on imaging, or new/worsening clinical symptoms. Kaplan-Meier analysis was used to estimate PFS for both groups and independent predictors of progression were assessed using Cox proportional hazards regression in the surgical cohort.</p> Results <p>During a median follow-up of 7.9 years (range: 5.0-46.9), tumor progression occurred in 67 patients (14.2%). Most progression 29/67 (89.6%) events occurred within the first 15 years of follow-up. Multivariate analysis identified residual tumor (HR = 5.1; 95% CI: 2.2–11.9; <i>p</i> &lt; 0.01) and aggressive histopathology (HR = 2.1; 95% CI: 1.1–3.8; <i>p</i> = 0.02) as significant independent predictors of progression. Neither gender, age, radiotherapy nor cabergoline treatment significantly altered progression risk in the multivariate model.</p> Conclusion <p>NFPAs show a gradual risk of progression over time, particularly during the first 15 years post-diagnosis. Postoperative residual tumor and aggressive histopathological features are the strongest predictors of progression, highlighting the importance of maximal safe resection when feasible and detailed histopathological assessment for risk stratification. These findings support long-term surveillance for high-risk patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study

  • 期刊论文

  • 发表日期：

    2025年8月8日

查看全文
  • Betina Biagetti,
  • Andres Cardona-Arias,
  • Edelmiro Menéndez Torre,
  • Anna Aulinas,
  • Ignacio Ruz-Caracuel,
  • Rogelio García Centeno,
  • Laura González,
  • Ana Irigaray Echarri,
  • María Dolores Moure Rodríguez,
  • Miguel Paja,
  • Fernando Guerrero-Pérez,
  • Justo P. Castaño,
  • María Dolores Ollero García,
  • Cristina Novo-Rodríguez,
  • Carmen Tenorio-Jimenéz,
  • Rocío Villar-Taibo,
  • Ignacio Bernabéu,
  • Everardo Díaz-López,
  • María Calatayud,
  • Cristina Alvarez-Escola,
  • Patricia Martín Rojas-Marcos,
  • José María Recio-Córdova,
  • Claudia Lozano-Aida,
  • Queralt Asla Roca,
  • María Dolores Aviles,
  • Elena López Mezquita,
  • María Fernández Argueso,
  • Inmaculada González Molero,
  • Iban Alberoa,
  • Cindy Idrobo,
  • Estefanía Achote,
  • Elena Martínez-Sáez,
  • Mónica Marazuela,
  • Manel Puig-Domingo,
  • Felicia Hanzu,
  • Marta Araujo-Castro

摘要

Background and purpose

Non-functioning pituitary adenomas (NFPAs) have an unpredictable clinical course, with recurrence and progression posing significant challenges. This study aims to evaluate progression-free survival (PFS) and identify predictors and patterns of tumor progression.

Methods

We conducted a retrospective multicenter study including 472 patients with NFPAs > 1 cm from 17 Spanish hospitals (416 surgical, 56 conservative management). Tumor progression was defined as > 20% increase in size, >2 mm growth on imaging, or new/worsening clinical symptoms. Kaplan-Meier analysis was used to estimate PFS for both groups and independent predictors of progression were assessed using Cox proportional hazards regression in the surgical cohort.

Results

During a median follow-up of 7.9 years (range: 5.0-46.9), tumor progression occurred in 67 patients (14.2%). Most progression 29/67 (89.6%) events occurred within the first 15 years of follow-up. Multivariate analysis identified residual tumor (HR = 5.1; 95% CI: 2.2–11.9; p < 0.01) and aggressive histopathology (HR = 2.1; 95% CI: 1.1–3.8; p = 0.02) as significant independent predictors of progression. Neither gender, age, radiotherapy nor cabergoline treatment significantly altered progression risk in the multivariate model.

Conclusion

NFPAs show a gradual risk of progression over time, particularly during the first 15 years post-diagnosis. Postoperative residual tumor and aggressive histopathological features are the strongest predictors of progression, highlighting the importance of maximal safe resection when feasible and detailed histopathological assessment for risk stratification. These findings support long-term surveillance for high-risk patients.